George Atiee
Worldwide Clinical Trials · ICON Development Solutions · Healthcare Discoveries, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name George Atiee as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:43 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04074317 · Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1DXeris Pharmaceuticals · completed · Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus · principal investigator
- Ph1/Ph2NCT03616223 · FX-322 in Sensorineural Hearing LossFrequency Therapeutics · completed · Sensorineural Hearing Loss · principal investigator
- Ph1NCT02446002 · Assessment of the Effect of Naltrexone on Lofexidine Single Dose Pharmacokinetics in Healthy SubjectsUSWM, LLC (dba US WorldMeds) · completed · Healthy · principal investigator
- N/ANCT01663220 · Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes MellitusFoundation for the National Institutes of Health · completed · Type 2 Diabetes · principal investigator
- N/ANCT01663207 · Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With PrediabetesFoundation for the National Institutes of Health · completed · Type 2 Diabetes · principal investigator
- N/ANCT01454973 · Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy SubjectsFoundation for the National Institutes of Health · completed · Type 2 Diabetes · principal investigator
- Ph1/Ph2NCT00519389 · Safety, Reactogenicity and Immunogenicity of an H5N1 VLPNovavax · completed · Pandemic Influenza · principal investigator
- Ph2NCT00419263 · Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.BioCryst Pharmaceuticals · completed · Influenza · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:43 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- R01DA030916RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT02446002
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:43 UTC. The ranking covers the 200 most relevant of 21 PubMed records, and a shared surname and initials can bring in a namesake. All 21 on PubMed
- First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers.Mov Disord · 2017198 citationsRCR 7.9
- 59 citationsRCR 1.8
- Improved Speech Intelligibility in Subjects With Stable Sensorineural Hearing Loss Following Intratympanic Dosing of FX-322 in a Phase 1b Study.Otol Neurotol · 202154 citationsRCR 3.8
- Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus.Clin Pharmacol Drug Dev · 201939 citationsRCR 2.4
- 36 citationsRCR 1.9
- A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects.J Thromb Haemost · 201731 citationsRCR 1.3
- Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers.Antimicrob Agents Chemother · 201129 citationsRCR 0.9
- Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis.Allergy Asthma Proc · 201228 citationsRCR 1.2
- An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.Clin Pharmacokinet · 201819 citationsRCR 0.7
- Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.J Clin Pharmacol · 200917 citationsRCR 0.5